Cargando…

What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis

PURPOSE: Combined therapy with transarterial chemoembolization (TACE) and apatinib is superior in therapeutic effect compared with TACE alone in patients with hepatocellular carcinoma (HCC). To determine the most suitable agent combined with apatinib for TACE treatment, we did a systematic review an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hui, Fuhai, Xu, Chang, Xu, Xiangbo, Chen, Jiangxia, Geng, Hefeng, Yang, Chao, Zhang, Yingshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174538/ https://www.ncbi.nlm.nih.gov/pubmed/35692745 http://dx.doi.org/10.3389/fonc.2022.887332

Ejemplares similares

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study
por: Xia, Wei-Li, et al.
Publicado: (2022)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study
por: Cao, Yanyan, et al.
Publicado: (2021)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
por: Sun, Tao, et al.
Publicado: (2020)

A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
por: Sun, Tao, et al.
Publicado: (2022)

Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
por: Brunner, Thomas B., et al.
Publicado: (2021)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Zhao, Ying, et al.
Publicado: (2021)

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres(®) Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis
por: Liang, Bin, et al.
Publicado: (2021)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer
por: Pocha, Pauline Viviane, et al.
Publicado: (2021)

Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
por: Gu, Huiying, et al.
Publicado: (2020)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
por: Zhou, Qunfang, et al.
Publicado: (2020)

Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment
por: Bian, Chao-fan, et al.
Publicado: (2022)

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study
por: Ouyang, Tao, et al.
Publicado: (2021)

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma
por: Duan, Xuhua, et al.
Publicado: (2022)

Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas' Responses to Transarterial Chemoembolization
por: Moawad, Ahmed W., et al.
Publicado: (2020)

Modified quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma after transarterial chemoembolization
por: Xu, Jiachen, et al.
Publicado: (2023)

Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma
por: Chen, Shiguang, et al.
Publicado: (2018)

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study [Retraction]
Publicado: (2022)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
por: Deng, Jun, et al.
Publicado: (2022)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
por: Sun, Liwei, et al.
Publicado: (2022)

Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization
por: Xu, Jing-Xuan, et al.
Publicado: (2023)

Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
por: Sharma, Rohini, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Endoscopic Therapy Is Beneficial for Unresectable Hepatocellular Carcinoma With Esophagogastric Varices
por: Tao, Ziwen, et al.
Publicado: (2021)

Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
por: Xia, Wei-Li, et al.
Publicado: (2022)

The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization
por: Chien, Tzu-Ping, et al.
Publicado: (2022)

Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis
por: Long, Jiaye, et al.
Publicado: (2023)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. (125)Iodine Implantation
por: Hu, Hong-Tao, et al.
Publicado: (2021)

Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
por: Lu, Linbin, et al.
Publicado: (2021)

Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
por: Pelizzaro, Filippo, et al.
Publicado: (2022)

Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
por: Jin, Zhi-Cheng, et al.
Publicado: (2021)

Prediction of bile duct injury after transarterial chemoembolization for hepatocellular carcinoma: Model establishment and verification
por: Guo, Jianxi, et al.
Publicado: (2022)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_393r85ij7f6sikmr1sg3lrvdri